Barbexaclone

Identification

Name
Barbexaclone
Accession Number
DB09001
Type
Small Molecule
Groups
Experimental
Description

Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties intended to offset these sedative effects. Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine. Several reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties. These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials. Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009.

Barbexaclone exists in 25mg and 100mg tablets. 100mg of barbexaclone is equivalent to 60mg of phenobarbital. With this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount of phenobarbital.

There has been a case of barbexaclone abuse due to the amphetamine like properties of propylhexedrine, although the comparative abuse potential is much lower than amphetamine.

Structure
Thumb
Synonyms
  • Barbexaclon
  • Barbexaclona
  • Barbexaclone
  • Barbexaclonum
Product Ingredients
IngredientUNIICASInChI Key
BarbexacloneNot AvailableNot AvailableNot applicable
International/Other Brands
Maliasin (Abbott)
Categories
UNII
291GX1YB65
CAS number
4388-82-3
Weight
Average: 387.524
Monoisotopic: 387.252191935
Chemical Formula
C22H33N3O3
InChI Key
MJCBWPMBFCUHBP-NPULLEENSA-N
InChI
InChI=1S/C12H12N2O3.C10H21N/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16;1-9(11-2)8-10-6-4-3-5-7-10/h3-7H,2H2,1H3,(H2,13,14,15,16,17);9-11H,3-8H2,1-2H3/t;9-/m.0/s1
IUPAC Name
5-ethyl-4,6-dihydroxy-5-phenyl-2,5-dihydropyrimidin-2-one; [(2S)-1-cyclohexylpropan-2-yl](methyl)amine
SMILES
[H][[email protected]](C)(CC1CCCCC1)NC.CCC1(C(O)=NC(=O)N=C1O)C1=CC=CC=C1

Pharmacology

Indication

Created for the treatment for epilepsy, with the intent of creating an antiepileptic with less sedative properties than phenobarbital.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Phenobarbitol targets GABA receptors in the CNS. Propylhexedrine is a TAAR1 agonist.

Absorption

After oral administration of barbexaclone in mice the maximum plasma levels of prophylhexedrine appeared after 4 minutes, and propylhexedrine was seen to penetrate the blood brain barrier rapidly. Bioavailability (AUC oral / AUC iv) = 0.37. [3] Phenobarbital was observed to reach the blood more slowly, and brain uptake was a slow process. Equilibrium concentrations with plasma reached after 30 minutes after i.v injection. [3]

Volume of distribution

In mice, the volume of distribution was 0.78L/kg of phenobarbital, and 19.3L/kg for propylhexedrine, after i.v. administration. [3] High but unequal tissue accumulation of propylhexedrine was observed in mice: lung = kidney > liver = brain > spleen > heart > skeletal muscle. [3]

Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

After IV administration in mice, levels of phenobarbital declined exponentially with a half life of 7.5h. [3] For propylhexedrine t0.5a = 0.31h and t0.5b = 2.5h.

Clearance
Not Available
Toxicity

Barbiturates are associated with congenital heart malformations, facial clefts, and other malformations. [5] There is no available data on the use of barbexaclone in pregnancy. One case of a 36 year old women who used barbexaclone 300mg/day and oxcarbezine 600mg/day for 2 years before the pregnancy and 10 weeks into pregnancy resulted in an uncomplicated delivery and normal physical, motor, and mental development at 24 months of age. [5]

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololBarbexaclone may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Barbexaclone.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Barbexaclone.Approved
AldesleukinBarbexaclone may increase the hypotensive activities of Aldesleukin.Approved
AliskirenBarbexaclone may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Barbexaclone.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Barbexaclone.Experimental, Investigational
AmifostineBarbexaclone may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideBarbexaclone may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Barbexaclone.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Barbexaclone.Approved
AmiodaroneBarbexaclone may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Barbexaclone.Approved
AmlodipineBarbexaclone may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe metabolism of Amoxapine can be increased when combined with Barbexaclone.Approved
Amphotericin BBarbexaclone may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Barbexaclone.Approved
Amyl NitriteBarbexaclone may increase the hypotensive activities of Amyl Nitrite.Approved
ApomorphineBarbexaclone may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineBarbexaclone may increase the hypotensive activities of Apraclonidine.Approved
ArotinololBarbexaclone may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideBarbexaclone may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
AtenololBarbexaclone may increase the hypotensive activities of Atenolol.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Barbexaclone.Approved, Investigational
Azilsartan medoxomilBarbexaclone may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Barbexaclone.Investigational
BarnidipineBarbexaclone may increase the hypotensive activities of Barnidipine.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Barbexaclone.Experimental
BenazeprilBarbexaclone may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe metabolism of Bencyclane can be increased when combined with Barbexaclone.Experimental
BendroflumethiazideBarbexaclone may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Barbexaclone.Approved, Investigational
BepridilBarbexaclone may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBarbexaclone may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Barbexaclone.Approved
BisoprololBarbexaclone may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Barbexaclone.Approved
BortezomibBarbexaclone may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumBarbexaclone may increase the hypotensive activities of Bretylium.Approved
BrimonidineBarbexaclone may increase the hypotensive activities of Brimonidine.Approved
BromocriptineBarbexaclone may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Barbexaclone.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Barbexaclone.Experimental, Investigational
BumetanideBarbexaclone may increase the hypotensive activities of Bumetanide.Approved
BupivacaineBarbexaclone may increase the hypotensive activities of Bupivacaine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Barbexaclone.Approved
CanagliflozinBarbexaclone may increase the hypotensive activities of Canagliflozin.Approved
Candesartan cilexetilBarbexaclone may increase the hypotensive activities of Candesartan cilexetil.Approved
CaptoprilBarbexaclone may increase the hypotensive activities of Captopril.Approved
CarbetocinBarbexaclone may increase the hypotensive activities of Carbetocin.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be increased when combined with Barbexaclone.Investigational
CaroverineThe metabolism of Caroverine can be increased when combined with Barbexaclone.Experimental
CarteololBarbexaclone may increase the hypotensive activities of Carteolol.Approved
CarvedilolBarbexaclone may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Barbexaclone.Approved, Investigational
ChloramphenicolThe metabolism of Barbexaclone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideBarbexaclone may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Barbexaclone.Investigational, Withdrawn
ChlorpromazineBarbexaclone may increase the hypotensive activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneBarbexaclone may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
CilazaprilBarbexaclone may increase the hypotensive activities of Cilazapril.Approved
CilnidipineBarbexaclone may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Barbexaclone.Approved, Investigational
ClevidipineBarbexaclone may increase the hypotensive activities of Clevidipine.Approved
ClofarabineBarbexaclone may increase the hypotensive activities of Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Barbexaclone.Approved, Vet Approved
ClonidineBarbexaclone may increase the hypotensive activities of Clonidine.Approved
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Barbexaclone.Experimental
ClorindioneThe metabolism of Clorindione can be increased when combined with Barbexaclone.Experimental
ClozapineBarbexaclone may increase the hypotensive activities of Clozapine.Approved
ConivaptanBarbexaclone may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated estrogensThe therapeutic efficacy of Conjugated estrogens can be decreased when used in combination with Barbexaclone.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Barbexaclone.Approved
CyclopenthiazideBarbexaclone may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Barbexaclone.Approved, Investigational, Vet Approved
DapagliflozinBarbexaclone may increase the hypotensive activities of Dapagliflozin.Approved
DarodipineThe metabolism of Darodipine can be increased when combined with Barbexaclone.Experimental
DesfluraneBarbexaclone may increase the hypotensive activities of Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Barbexaclone.Approved
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Barbexaclone.Approved
DexmedetomidineBarbexaclone may increase the hypotensive activities of Dexmedetomidine.Approved, Vet Approved
DibenzepinThe metabolism of Dibenzepin can be increased when combined with Barbexaclone.Experimental
DiclofenamideBarbexaclone may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Barbexaclone.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Barbexaclone.Approved, Investigational
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Barbexaclone.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Barbexaclone.Approved, Investigational
DiltiazemBarbexaclone may increase the hypotensive activities of Diltiazem.Approved
DinutuximabBarbexaclone may increase the hypotensive activities of Dinutuximab.Approved
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Barbexaclone.Experimental
DipyridamoleBarbexaclone may increase the hypotensive activities of Dipyridamole.Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Barbexaclone.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Barbexaclone.Investigational
DoxazosinBarbexaclone may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Barbexaclone.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Barbexaclone.Approved, Investigational, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbexaclone.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Barbexaclone.Approved
EfonidipineBarbexaclone may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinBarbexaclone may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilBarbexaclone may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBarbexaclone may increase the hypotensive activities of Enalaprilat.Approved
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Barbexaclone.Experimental
EperisoneThe metabolism of Eperisone can be increased when combined with Barbexaclone.Approved, Investigational
EplerenoneBarbexaclone may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolBarbexaclone may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBarbexaclone may increase the hypotensive activities of Eprosartan.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Barbexaclone.Investigational
EsmololBarbexaclone may increase the hypotensive activities of Esmolol.Approved
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Barbexaclone.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Barbexaclone.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Barbexaclone.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Barbexaclone.Approved
Etacrynic acidBarbexaclone may increase the hypotensive activities of Etacrynic acid.Approved
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbexaclone.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbexaclone.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbexaclone.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Barbexaclone.Approved, Investigational
FelbamateThe serum concentration of Barbexaclone can be increased when it is combined with Felbamate.Approved
FelodipineBarbexaclone may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineThe metabolism of Fendiline can be increased when combined with Barbexaclone.Withdrawn
FenoldopamBarbexaclone may increase the hypotensive activities of Fenoldopam.Approved
FimasartanBarbexaclone may increase the hypotensive activities of Fimasartan.Approved, Investigational
FluindioneThe metabolism of Fluindione can be increased when combined with Barbexaclone.Investigational
FlunarizineThe metabolism of Flunarizine can be increased when combined with Barbexaclone.Approved
FosinoprilBarbexaclone may increase the hypotensive activities of Fosinopril.Approved
FurosemideBarbexaclone may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe metabolism of Gabapentin can be increased when combined with Barbexaclone.Approved, Investigational
GallopamilThe metabolism of Gallopamil can be increased when combined with Barbexaclone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Barbexaclone.Approved, Investigational
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Barbexaclone.Approved, Vet Approved
GuanfacineBarbexaclone may increase the hypotensive activities of Guanfacine.Approved, Investigational
HalothaneBarbexaclone may increase the hypotensive activities of Halothane.Approved, Vet Approved
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Barbexaclone.Withdrawn
HydralazineBarbexaclone may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBarbexaclone may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBarbexaclone may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbexaclone.Approved
IloprostBarbexaclone may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilBarbexaclone may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Barbexaclone.Approved
IndapamideBarbexaclone may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Barbexaclone.Withdrawn
IndoraminBarbexaclone may increase the hypotensive activities of Indoramin.Withdrawn
IprindoleThe metabolism of Iprindole can be increased when combined with Barbexaclone.Experimental
IrbesartanBarbexaclone may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidBarbexaclone may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneBarbexaclone may increase the hypotensive activities of Isoflurane.Approved, Vet Approved
Isosorbide DinitrateBarbexaclone may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateBarbexaclone may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineBarbexaclone may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineBarbexaclone may increase the hypotensive activities of Isradipine.Approved
LabetalolBarbexaclone may increase the hypotensive activities of Labetalol.Approved
LacidipineBarbexaclone may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Barbexaclone.Approved, Investigational
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Barbexaclone.Investigational
LercanidipineBarbexaclone may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololBarbexaclone may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineBarbexaclone may increase the hypotensive activities of Levobupivacaine.Approved, Investigational
LevodopaBarbexaclone may increase the hypotensive activities of Levodopa.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Barbexaclone.Approved, Investigational
LevosimendanBarbexaclone may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidoflazineThe metabolism of Lidoflazine can be increased when combined with Barbexaclone.Experimental
LisinoprilBarbexaclone may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofepramineThe metabolism of Lofepramine can be increased when combined with Barbexaclone.Experimental
LofexidineBarbexaclone may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanBarbexaclone may increase the hypotensive activities of Losartan.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Barbexaclone.Investigational
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Barbexaclone.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Barbexaclone.Approved, Investigational
MannitolBarbexaclone may increase the hypotensive activities of Mannitol.Approved, Investigational
MecamylamineBarbexaclone may increase the hypotensive activities of Mecamylamine.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbexaclone.Approved, Investigational
MefloquineThe therapeutic efficacy of Barbexaclone can be decreased when used in combination with Mefloquine.Approved
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Barbexaclone.Experimental
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Barbexaclone.Approved
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbexaclone.Experimental
MethazolamideBarbexaclone may increase the hypotensive activities of Methazolamide.Approved
MethyclothiazideBarbexaclone may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaBarbexaclone may increase the hypotensive activities of Methyldopa.Approved
MetipranololBarbexaclone may increase the hypotensive activities of Metipranolol.Approved
MetolazoneBarbexaclone may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololBarbexaclone may increase the hypotensive activities of Metoprolol.Approved, Investigational
MianserinThe therapeutic efficacy of Barbexaclone can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be increased when combined with Barbexaclone.Investigational, Withdrawn
MinoxidilBarbexaclone may increase the hypotensive activities of Minoxidil.Approved
MirtazapineThe metabolism of Mirtazapine can be increased when combined with Barbexaclone.Approved
MoexiprilBarbexaclone may increase the hypotensive activities of Moexipril.Approved
MorphineBarbexaclone may increase the hypotensive activities of Morphine.Approved, Investigational
MoxonidineBarbexaclone may increase the hypotensive activities of Moxonidine.Approved, Investigational
NabiloneBarbexaclone may increase the hypotensive activities of Nabilone.Approved, Investigational
NadololBarbexaclone may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Barbexaclone.Investigational
NebivololBarbexaclone may increase the hypotensive activities of Nebivolol.Approved, Investigational
NesiritideBarbexaclone may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineBarbexaclone may increase the hypotensive activities of Nicardipine.Approved
NifedipineBarbexaclone may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Barbexaclone.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Barbexaclone.Experimental
NilvadipineBarbexaclone may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be increased when combined with Barbexaclone.Approved, Investigational, Withdrawn
NimodipineBarbexaclone may increase the hypotensive activities of Nimodipine.Approved
NisoldipineBarbexaclone may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineBarbexaclone may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideBarbexaclone may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinBarbexaclone may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideBarbexaclone may increase the hypotensive activities of Nitroprusside.Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Barbexaclone.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Barbexaclone.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Barbexaclone.Approved
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Barbexaclone.Approved
ObinutuzumabBarbexaclone may increase the hypotensive activities of Obinutuzumab.Approved
OlmesartanBarbexaclone may increase the hypotensive activities of Olmesartan.Approved, Investigational
OpipramolThe metabolism of Opipramol can be increased when combined with Barbexaclone.Investigational
OrlistatThe serum concentration of Barbexaclone can be decreased when it is combined with Orlistat.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be increased when combined with Barbexaclone.Experimental, Investigational
OxprenololBarbexaclone may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelBarbexaclone may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PapaverineBarbexaclone may increase the hypotensive activities of Papaverine.Approved
PenbutololBarbexaclone may increase the hypotensive activities of Penbutolol.Approved, Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Barbexaclone.Approved, Investigational
PerindoprilBarbexaclone may increase the hypotensive activities of Perindopril.Approved
PethidineBarbexaclone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineBarbexaclone may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Barbexaclone.Approved, Investigational
PhenoxybenzamineBarbexaclone may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Barbexaclone.Approved, Investigational
PhentolamineBarbexaclone may increase the hypotensive activities of Phentolamine.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Barbexaclone.Approved
PindololBarbexaclone may increase the hypotensive activities of Pindolol.Approved
PipamperoneBarbexaclone may increase the hypotensive activities of Pipamperone.Approved, Investigational
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Barbexaclone.Experimental
PolythiazideBarbexaclone may increase the orthostatic hypotensive activities of Polythiazide.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Barbexaclone.Approved
PramipexoleBarbexaclone may increase the hypotensive activities of Pramipexole.Approved, Investigational
PrazosinBarbexaclone may increase the hypotensive activities of Prazosin.Approved
PregabalinThe metabolism of Pregabalin can be increased when combined with Barbexaclone.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Barbexaclone.Withdrawn
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Barbexaclone.Approved, Vet Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Barbexaclone.Approved, Investigational
PropofolBarbexaclone may increase the hypotensive activities of Propofol.Approved, Investigational, Vet Approved
PropranololBarbexaclone may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Barbexaclone.Approved
PyridoxineThe metabolism of Barbexaclone can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuetiapineBarbexaclone may increase the hypotensive activities of Quetiapine.Approved
QuinaprilBarbexaclone may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneBarbexaclone may increase the orthostatic hypotensive activities of Quinethazone.Approved
RamiprilBarbexaclone may increase the hypotensive activities of Ramipril.Approved
RasagilineBarbexaclone may increase the hypotensive activities of Rasagiline.Approved
RemifentanilBarbexaclone may increase the hypotensive activities of Remifentanil.Approved
ReserpineBarbexaclone may increase the hypotensive activities of Reserpine.Approved, Investigational
RifabutinThe metabolism of Barbexaclone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Barbexaclone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Barbexaclone can be increased when combined with Rifapentine.Approved
RifaximinThe metabolism of Barbexaclone can be increased when combined with Rifaximin.Approved, Investigational
RiociguatBarbexaclone may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Barbexaclone.Approved, Investigational
RopiniroleBarbexaclone may increase the hypotensive activities of Ropinirole.Approved, Investigational
RopivacaineBarbexaclone may increase the hypotensive activities of Ropivacaine.Approved
RotigotineBarbexaclone may increase the hypotensive activities of Rotigotine.Approved
SacubitrilBarbexaclone may increase the hypotensive activities of Sacubitril.Approved
SelegilineBarbexaclone may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SevofluraneBarbexaclone may increase the hypotensive activities of Sevoflurane.Approved, Vet Approved
Sodium NitriteBarbexaclone may increase the hypotensive activities of Sodium Nitrite.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Barbexaclone.Approved, Investigational
SotalolBarbexaclone may increase the hypotensive activities of Sotalol.Approved
SpironolactoneBarbexaclone may increase the hypotensive activities of Spironolactone.Approved
StreptokinaseBarbexaclone may increase the hypotensive activities of Streptokinase.Approved, Investigational
SufentanilBarbexaclone may increase the hypotensive activities of Sufentanil.Approved, Investigational
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Barbexaclone.Approved
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Barbexaclone.Investigational
TamsulosinBarbexaclone may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TelmisartanBarbexaclone may increase the hypotensive activities of Telmisartan.Approved, Investigational
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Barbexaclone.Approved
TerazosinBarbexaclone may increase the hypotensive activities of Terazosin.Approved
TerodilineThe metabolism of Terodiline can be increased when combined with Barbexaclone.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Barbexaclone.Experimental
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be increased when combined with Barbexaclone.Investigational
ThalidomideBarbexaclone may increase the hypotensive activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Barbexaclone.Approved
ThioridazineBarbexaclone may increase the hypotensive activities of Thioridazine.Approved, Withdrawn
TianeptineThe metabolism of Tianeptine can be increased when combined with Barbexaclone.Approved, Investigational
TimololBarbexaclone may increase the hypotensive activities of Timolol.Approved
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Barbexaclone.Experimental
TizanidineBarbexaclone may increase the hypotensive activities of Tizanidine.Approved
TolazolineBarbexaclone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeBarbexaclone may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Barbexaclone.Approved
TorasemideBarbexaclone may increase the hypotensive activities of Torasemide.Approved
TrandolaprilBarbexaclone may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Barbexaclone.Approved, Investigational
TranylcypromineBarbexaclone may increase the hypotensive activities of Tranylcypromine.Approved
TretinoinBarbexaclone may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneBarbexaclone may increase the hypotensive activities of Triamterene.Approved
TrichlormethiazideBarbexaclone may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Barbexaclone.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Barbexaclone.Approved
Valproic AcidThe serum concentration of Barbexaclone can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanBarbexaclone may increase the hypotensive activities of Valsartan.Approved, Investigational
VerapamilBarbexaclone may increase the hypotensive activities of Verapamil.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Barbexaclone.Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Barbexaclone.Approved, Investigational
WarfarinThe metabolism of Warfarin can be increased when combined with Barbexaclone.Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Barbexaclone.Approved
ZiconotideThe metabolism of Ziconotide can be increased when combined with Barbexaclone.Approved
Food Interactions
Not Available

References

General References
  1. Bolukbasi F, Delil S, Bulus E, Senturk A, Yeni N, Karaagac N: End of the barbexaclone era: an experience of treatment withdrawal. Epileptic Disord. 2013 Sep;15(3):311-3. doi: 10.1684/epd.2013.0605. [PubMed:23981808]
  2. Iven H, Feldbusch E: Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. Naunyn Schmiedebergs Arch Pharmacol. 1983 Sep;324(2):153-9. [PubMed:6139756]
  3. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI: Barbexaclone use in pregnancy. Saudi Med J. 2004 Feb;25(2):245-6. [PubMed:14968233]
  4. Shorvon, Simon D.;Dodson, W. E.;Fish, David;Perucca, Emilio;Aminoff, Michael J. (2004). The Treatment of Epilepsy (2nd ed.). John Wiley & Sons. [ISBN:0-632-06046-8]
External Links
PubChem Compound
71196
PubChem Substance
347827816
ChemSpider
64332
Drugs.com
Drugs.com Drug Page
Wikipedia
Barbexaclone
ATC Codes
N03AA04 — Barbexaclone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.272 mg/mLALOGPS
logP1.44ALOGPS
logP2.14ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)0.97ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.25 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity60.39 m3·mol-1ChemAxon
Polarizability22.47 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas / Diazinanes / Benzene and substituted derivatives / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Barbiturate / Ureide / N-acyl urea / Monocyclic benzene moiety / 1,3-diazinane / Benzenoid / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 17, 2014 10:50 / Updated on December 01, 2017 16:11